City leaders share real-world GLP-1 coverage tactics, showing how public employers balance access, costs, and lasting ...

During her tenure as the Director of Employee Benefits, City of Wilmington, Delaware Dany B. Smith achieved remarkable ...

Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the ...

Deputy Chief for Benefits Administration for the City of Philadelphia since 2015. In her role as the City’s benefits leader, Marsha brings international experience as a Human Resources professional, ...

Catherine Gaffigan, MD, Elevance Health's President of Health Solutions, discusses value-based care initiatives and ...

Higher baseline monocyte counts, along with preserved basophils and low C-reactive protein, independently predict complete remission on anti-IgE therapy for CSU.

Kathrin Dvir, MD, MSc, discusses how biomarker-driven care, targeted therapies, and evolving sequencing are shaping modern breast cancer treatment.

Prostate cancer has been of the major areas of research for radioligand therapies. Last year, Novartis officials estimated that the March 28, 2025, FDA approval for Pluvicto in metastatic ...

A US-focused cohort study published in 2023 showed similar trends, with a higher AA incidence observed among women (range, 108.53-118.56) vs men (range, 63.68-72.09) and adults (range, 95.45-102.63) ...

Experts discuss how treatment strategies for NSCLC differ between resectable and metastatic disease, emphasizing a multimodal, curative approach in early-stage cancer versus personalized systemic ...

Updated NCCN pediatric STS guidelines emphasize risk stratification, imaging, multimodal therapy, and clinical trial enrollment to improve outcomes. The National Comprehensive Cancer Network (NCCN) ...

Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies.